Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: Review of the literature

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 1, 2011, Pages 21-30

  Arslan, Cagatay ^a   Sari, Ebru ^a   Aksoy, Sercan ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Discordance; HER 2; Hormone receptors; Metastatic; Primary

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; HORMONE RECEPTOR; LETROZOLE; PROGESTERONE; TAMOXIFEN; TRASTUZUMAB;

BIOLOGICAL PHENOMENA AND FUNCTIONS; BREAST BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CELL HETEROGENEITY; CELL SUBPOPULATION; CORRELATION ANALYSIS; HUMAN; INFORMATION RETRIEVAL; LABORATORY TEST; PRIMARY TUMOR; PROTEIN EXPRESSION; REVIEW; SCIENTIFIC LITERATURE; TREATMENT PLANNING;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL;

EID: 78650219264     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.537260     Document Type: Review

References (54)

1. Campbell FC, Blamey RW, Elston CW, et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1981;2:1317-19
2. Lower EE, Glass EL, Bradley DA, et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90:65-70
3. Holdaway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983;52:479-85
4. Regitnig P, Schippinger W, Lindbauer M, et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004;203:918-26
5. Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552-6
6. Osborne CK. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 1985;12:317-26
7. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-43
8. Hawkins RA, Black R, Steele RJ, et al. Oestrogen receptor concentration in primary breast cancer and axillary node metastases. Breast Cancer Res Treat 1981;1:245-51
9. Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113:301-6
10. Thor A. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? J Natl Cancer Inst 2001;93:1120-1
11. Fehm T, Becker S, Duerr-Stoerzer S, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007;9:R74
12. Li BD, Byskosh A, Molteni A, Duda RB. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994;57:71-7
13. Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-9
14. Spataro V, Price K, Goldhirsch A, et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992;3:733-40
15. Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20:1499-504
16. Guarneri V, Giovannelli S, Ficarra G, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management. Oncologist 2008;13:838-44
17. Sari E, Guler G, Hayran M, et al. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2010 [Epub ahead of print; doi: 10.1007/s12032-010-9418-2]
18. Karlsson E, Lindstrom LS, Wilking U, et al. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 2010;28(15s):abstract 1009
19. Liedtke C, Broglio K, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953-8
20. Wu J, Fackler MJ, Halushka MK, et al. Heterogeneity of breast cancer metastases: Comparison od therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008;14:1938-46
21. Amir E, Clemons M, Freedman OC, et al. Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. J Clin Oncol 2010;28(15s):abstract 1007
22. Locatelli MA, Curigliano G, Fumagalli L, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol 2010;28(18s):abstract CRA1008
23. Wilking U, Skoog L, Elmberger G, et al. HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients [Abstract]. J Clin Oncol 2007;25(18 Suppl):1023
24. Broom RJ, Tang PA, Simmons C, et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: Discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557-62
25. MacFarlane R, Speers C, Masoudi H, et al. Molecular changes in the primary breast cancer versus the relapsed/ metastatic lesion from a large population-based database and tissue microarray series [Abstract]. J Clin Oncol 2008;26(15 Suppl):1000
26. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103:1763-9
27. Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007;9:R31
28. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008;122:999-1004
29. Lacroix H, Iglehart JD, Skinner MA, Kraus MH. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989;4:145-51
30. Iglehart JD, Kraus MH, Langton BC, et al. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990;50:6701-7
31. Cardoso F, Di Leo A, Larsimont D, et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001;12:615-20
32. Symmans WF, Liu J, Knowles DM, Inghirami G. Breast cancer heterogeneity: Evaluation of clonality in primary and metastatic lesions. Hum Pathol 1995;26:210-16
33. Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-6
34. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 2000;30:259-65
35. Shimizu C, Fukutomi T, Tsuda H, et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000;73:17-20
36. Xu R, Perle MA, Inghirami G, et al. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and - nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 2002;15:116-24
37. Vincent-Salomon A, Jouve M, Genin P, et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002;94:2169-73
38. Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005;104:257-63
39. Liedtke C, Broglio C, Moulder S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953-8
40. Gown AM. Current issues in ER and HER2 testing by HC in breast cancer. Mod pathol 2008;21(Suppl 2):S8-15
41. Gong Y, Symmans WF, Krishnamurthy S, et al. Optimal fixation conditions for immunohistochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma. Cancer 2004;102:34-40
42. Kamby C, Rasmussen BB, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989;60:252-7
43. Hull DF III, Clark GM, Osborne CK, et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983;43:413-16
44. Umekita Y, Sagara Y, Yoshida H. Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer. Jpn J Cancer Res 1998;89:27-32
45. Edgerton SM, Moore D II, Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003;11:214-21
46. Bieche I, Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes Cancer 1995;14:227-51
47. Pertschuk LP, Axiotis CA, Feldman JG, et al. Marked intratumoral heterogeneity of the Proto-Oncogene Her-2/neu determined by three different detection systems. Breast J 1999;5:369-74
48. Rasbridge SA, Gillett CE, Seymour AM, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994;70:335-41
49. Teixeira MR, Pandis N, Bardi G, et al. Clonal heterogeneity in breast cancer: Karyotypic comparisons of multiple intraand extra-tumorous samples from 3 patients. Int J Cancer 1995;63:63-8
50. Teixeira MR, Pandis N, Bardi G, et al. Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res 1996;56:855-9
51. Kerbel RS. Growth dominance of the metastatic cancer cell: Cellular and molecular aspects. Adv Cancer Res 1990;55:87-132
52. Kuukasjarvi T, Karhu R, Tanner M, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997;57:1597-604
53. Manjili MH, Kmieciak M. Does HER-2/ neu antigen loss in metastatic breast tumors occur under immune pressure? Int J Cancer 2008;123:1476-7; author reply 8-9
54. Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 2007;37:675-85